Table 3 Published reports of the prognostic value of Ki-67 in multivariate analyses with hazard ratio’s (HR) after adjument for covariates with prostate cancer-survival as end point

From: Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments

Reference

Cohort type

Cohort size

Cutoff (%)

p-value

HR (95% CI)

Covariates

Stattin et al. [13]

TURP, WW

125

3

0.0023

2.51 (1.39–4.53)

G T A

Li et al. [14]

RX

108

3.5

0.009

4.24 (1.43–12.57)

G T Tx

Pollack et al. [15]

RX

496

cont

0.001

3.64 (2.15–6.16)

G T P Tx

Pollack et al. [15]

RX

496

7.1

0.0174

2.07 (1.14–3.76)

G T P Tx

Berney et al. [5]

TURP, WW

685

5

0.0003

1.83 (1.33–2.53)

G P Px

Khor et al. [16]

RX

637

11.3

0.0007

2.35 (1.43–3.85)

G T A Tx

Fisher et al. [6]

BX, WW

293

10

0.011

2.66 (1.36–5.2)

G P

Verhoven et al. (2013)

BX RX

468

6.2

0.0064

2.91 (1.35–6.26)

A G P T

Tollefson et al. [17]

BX

451

cont

0.001

1.11 (1.07–1.15)

G Px

Tretiakova et al. [18]

RP

1004

cont

0.02

1.10 (1.02–1.18)

G P Px

Tretiakova et al. [18]

RP

1004

5

ns

 

G P Px

Lobo et al. [19]

BX

189

5.33

<0,05

1.91 (1.01–3.57)

A G T

Kammerer-Jacquet et al. (this paper)

BX, WW

756

cont

0.001

1.08 (1.06–1.10)

A E G P

Kammerer-Jacquet et al (this paper)

BX, WW

756

5

0.007

1.93 (1.32–2.81)

A E G P

  1. A age, BX needle biopsy, CI confidence interval, CONT continuous, E extent, G Gleason grade, ns not significant, P prostate-specific antigen, PCS prostate cancer-specific survival, PCR prostate cancer recurrence, Px pathological features, RP radical prostatectomy, RX radiotherapy, T clinical stage, Tx treatment, TURP transurethral resection of the prostate, WW watchful waiting